Detalhe da pesquisa
1.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
2.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926
3.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602290
4.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
5.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593565
6.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359490
7.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861537
8.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Int J Gynecol Cancer
; 29(9): 1396-1404, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685558
9.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916367
10.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
11.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
12.
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
EBioMedicine
; 89: 104477, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36801617
13.
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Cancer Chemother Pharmacol
; 89(5): 671-682, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397664
14.
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Clin Pharmacokinet
; 61(11): 1477-1493, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107395
15.
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
JAMA Oncol
; 7(12): 1772-1781, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647981
16.
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Med
; 10(20): 7162-7173, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34549539
17.
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Nat Commun
; 12(1): 2487, 2021 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941784
18.
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
J Clin Oncol
; 38(30): 3494-3505, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32840418
19.
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Clin Pharmacol Drug Dev
; 8(1): 107-118, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29799676
20.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 9(2): 210-219, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425037